BOCA RATON, FL--(Marketwire - Dec 4, 2012) - Noble Financial Capital Markets (Noble) announced today that it has established a scientific advisory board (SAB). Jules Musing, a Large Pharma veteran who will chair the Board, is excited about the developmental prospects for the SAB. "Establishment of this Board represents a bold strategic initiative for Noble," said Musing. "Not only are innovations in the Healthcare sector moving forward at a blistering speed, the regulatory and scientific process has become exceedingly complex and it takes this kind of commitment to establish credibility with the various constituents," he said.
According to Noble's President, Nico P. Pronk, the SAB is a logical extension of the services provided to its investment banking, merchant banking, and corporate advisory clients. "These are seasoned professionals with extensive experience in cutting edge academic and clinical research, as well as Big Pharma business development, licensing, M&A, IP and R&D pipeline strategy," said Pronk. "We are honored to partner with them, and believe that their breadth of experience and network will be of great value to our clients and the Noble healthcare team."
Noble's Scientific Board of Advisors is comprised of the following professionals:
Kapil Dhingra, M.D.
Dr. Kapil Dhingra was formerly Vice President and the Head of the Oncology Disease Biology Leadership Team with Hoffman-La Roche. He is an experienced oncologist, drug developer and pharmaceutical executive with a proven track record in academic research, patient care and drug development from initiation through phase IV. Prior to joining the industry, he had a successful academic career at M.D. Anderson Cancer Center. He has been a member of the Board of Directors of Micromet and Biovex. Presently, he serves on the Boards of Algeta, Exosome Diagnostics and YM Biosciences and is an advisor to a number of biotechnology and pharmaceutical companies.
Victor Hartmann, M.D.
Dr. Victor Hartmann was formerly the head of Corporate and Strategic Development at Vertex Pharmaceuticals (
Robert Karr, M.D.
Dr. Karr formerly served as President of Idera Pharmaceuticals (
Michael Keller, J.D.
Mr. Keller is a partner with the law firm Roetzel & Andress. Throughout his 20-plus legal career, Mr. Keller has focused on patent prosecution, counseling and licensing of therapeutic, diagnostic, pharmaceutical and medical device products. He has negotiated complex product acquisition agreements with companies such as Bristol Myers Squibb, Glaxo Wellcome, P&G and Pfizer, and has evaluated more than 600 product acquisition candidates.
Jules A. Musing, Chairman
Mr. Musing is the former Global Head of Biotechnology Licensing and Business Development and has been responsible for global Drug Licensing at Johnson & Johnson (
Staf Van Reet, Ph.D.
Dr. Van Reet is a former executive at Johnson & Johnson who lead corporate venturing activities in Europe and was a member of the J&J Pharma Group Operating Committee. He has been responsible for all worldwide R&D activities of the Janssen Group of Companies as President of the Janssen Research Foundation and has been Managing Director of Janssen Pharmaceutica N.V. and Janssen Biotech. Dr. Van Reet is an accomplished Belgian scientist and businessman, who is currently the Managing Director of Viziphar Biosciences and on the Boards of several companies including, Actogenix, Okapi Sciences, Octoplus, Thrombogenix, Biocartis and Therasolve.
Noble Financial Capital Markets, established in 1984, is an equity research-driven, investment banking / corporate advisory boutique with concentration in the healthcare, technology, media, telecommunications and business services sectors.